N-TERMINAL BRAIN NATRIURETIC PROPEPTIDE AS A MARKER OF MULTIFOCAL ATHEROSCLEROSIS IN PATIENTS WITH ST SEGMENT ELEVATION MYOCARDIAL INFARCTION

Aim. To investigate the association between serum levels of N‑terminal brain natriuretic propeptide(Nt-proBNP)andtheseverityofcoronaryandnon-coronaryatherosclerosisin patients with myocardial infarction and ST segment elevation (STEMI). Material and methods. The study included 186 STEMI patients. All participants underwent coronary angiography and angioplasty with infarct-related artery stenting, as well as the screening assessment of non-coronary atherosclerosis of brachiocephalic arteries and large lower extremity arteries. The measurement of Nt-proBNP levels was performed 10–14 days after the STEMI onset. Results. Nt-proBNP levels were not associated with the severity of coronary atherosclerosis. However, patients with more advanced non-coronary atherosclerosis and a higher number of affected non-coronary vessels demonstrated elevated Nt-proBNP concentrations. After adjustment for age, severity of heart failure and myocardial dysfunction, Nt-proBNP were still associated with atherosclerosis multifocality. Conclusion. In STEMI patients, Nt-proBNP concentrations were associated with severity and multifocality of non-coronary atherosclerosis. This could be used in clinical practice for predicting the risk of repeat atherosclerotic cardiovascular events.

atherosclerosis, myocardial infarction, brain natriuretic propeptide

1. Barbarash L.S., Kashtalap V.V., Zykov M.V. et al. Prevalence and clinical significance of polyvascular artery disease in patients with ST elevation myocardial infarction. Cardiology and cardiovascular surgery 2010, 5: 31–36. Russian (Барбараш Л.С., Кашталап В.В., Зыков М.В и др. Распространенность и клиническая значимость мультифокального атеросклероза у пациентов с инфарктом миокарда и подъемом сегмента ST. Кардиология и сердечно-сосудистая хирургия 2010, 5:31–36).

2. Dudanov I.P., Petrovskiy V.I., Subbotina N.S. Polyvascular artery disease: clinical and pathogenetic aspects of ischemic organ injury. Petrozavodsk: 2004, р.240 Russian (Дуданов И. П., Петровский В.И., Субботина Н. С. Мультифокальный атеросклероз: клинико-патогенетические аспекты ишемических органных поражений. Петрозаводск: 2004, с. 240).

3. Barbarash O.L., Zykov M.V., Kashtalap V.V. et al. Prognostic value of different inflammation markers in ST elevation myocardial infarction. Cardiology 2011, 3: 24–30. Russian (Барбараш О. Л., Зыков М.В., Кашталап В.В. и др. Прогностическая ценность различных маркеров воспаления при инфаркте миокарда с подъемом сегмента ST. Кардиология 2011, 3:24–30).

4. Shavrin A.P., Khovaeva Ja.B., Chereshnev V.A. et al. Inflammation markers in atherogenesis. Cardiovascular therapy and prevention 2009, 3: 13–15. Russian (Шаврин А.П., Ховаева Я.Б., Черешнев В.А. и др. Маркёры воспаления в процессе развития атеросклероза. Кардиоваскулярная терапия и профилактика 2009, 3:13–15).

5. Ruda M. Y.,Shakhnovich R.M.,Shreyder E.V. Prognostic influenceofinflammation markers and NT-proBNP in different ACS management strategies. Cardiology bulletin. 2008; Т. III 2: 44–52. Russian (Руда М.Я., Шахнович Р.М., Шрейдер Е.В. Прогностическое влияние маркеров воспаления и NT-proBNP при различных вариантах лечения больных с ОКС. Кардиол. вестн. 2008, Т. III, 2:44–52).

6. Belenkov Y.N., Mareev V.Y, Ageev F. T. Heart failure paradoxes: a turn of century’s perspective. Heart failure. 2000, 1:4–7. Russian (Беленков Ю. Н., Мареев В.Ю., Агеев Ф.Т. Парадоксы сердечной недостаточности: взгляд на проблему на рубеже веков Сердеч. недостаточность. 2000, 1:4–7).

7. Mitkovskaya N.P., Gerasimenok D.S., Khodosovskaya E.V. et al. Inflammation response activity in patients with acute coronary syndrome and acute ischemic brain injury. Medical Journal 2008, 3:34–37. Russian (Митьковская Н. П., Герасименок Д. С., Ходосовская Е.В. и др. Активность воспалительного ответа у пациентов с сочетанием острого коронарного синдрома и острого ишемического повреждения мозга. Мед. журн. 2008, 3: 34–37).

8. Palazzuoli A., Gennari L., Calabria P. et al. Relation of plasma brain natriuretic peptide levels in non-ST- elevation coronary disease and preserved systolic function to number of narrowed coronary arteries.J. Am. Coll. Cardiol. 2005; 96:1705–10.

9. Morrow D.A., de Lemos J.A., Sabatine M.S. et al. Evaluation of B type natriuretic peptide for risk assessment in unstable angina/non- ST-elevation myocardial infarctionB type natriuretic peptide and prognosis in TACTICS-TIMI 18. J. Am. Coll. Cardiol. 2003; 41:1264–72.

10. Shrejder E.V., Shahnovich R.M., Kaznacheeva E.I. Comparative dynamics of inflammation markers and NT-proBNP in different management strategies of acute coronary syndrome patients. Cardiology 2008, 8: 20–27. Russian (Шрейдер Е.В., Шахнович Р. М., Казначеева Е. И. Сравнительная динамика маркеров воспаления и NT-proBNP при различных вариантах лечения больных с острым коронарным синдромом. Кардиология. 2008, 8: 20–27).

11. G. McDowell, C. Shaw, K. Buchanan et al. The natriuretic peptide family. Eur.J. Clin. Invest. 1995; 25:291–298.

12. Rogers R.K., May H.T., Anderson J.L. et al. Prognostic value of B type natriuretic peptide for cardiovascular events independent of left ventricular end-diastolic pressure. American Heart Journal. 2009;158; 5:.777–83.

13. B. Lindahl, J. Lindback, T. Jernberg et al. Serial analyses of N terminal pro-B type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy.J. Am. Coll. Cardiol. 2005; 45:533–541.

14. De Lemos, J.A. Natriuretic peptides in the prognosis and management of acute coronary syndromes.J. A. de Lemos, W.F. Peacock, P.A. McCullough. Rev. Cardiovasc. Med. 2010; 11, 2: 24–34.

15. А. Bold, М. Bold. Determinants of natriuretic peptide production by the heart: basic and clinical implications.J. Invest. Med. 2005; 53, 7:371–377.